Six trials posted results this week, from PTSD to liver cancer
Brigimadlin for solid tumors, ketamine for PTSD, a liver-cancer triple combo, bupivacaine for surgical pain, glucagon in metabolic disease, and revefenacin in COPD all reached completed-with-results.
- Brightline-2 (NCT05512377), a Phase 2 trial of brigimadlin (BI 907828) sponsored by Boehringer Ingelheim, is completed. It enrolled patients with pancreatic neoplasms, solid tumors, biliary tract cancer, lung neoplasms, and bladder cancer. m:…2404
- The Minneapolis Veterans Affairs Medical Center completed a Phase 2 trial (NCT03960658) testing ketamine-enhanced prolonged exposure for PTSD. The study is officially recorded as completed with results. m:…0614
- A Bristol-Myers Squibb Phase 2 trial (NCT05337137) of nivolumab, relatlimab, and bevacizumab in advanced hepatocellular carcinoma is completed with results posted. The study tested the triple combination against a placebo. m:…7036
- A Phase 4 trial (NCT04362566) of bupivacaine for postoperative pain in Mohs surgery, run against a placebo saline intervention, is completed with results posted. Sponsors were the University of Missouri-Columbia, the University of Pennsylvania, and Columbia University. m:…2141
- A Phase 2 trial (NCT05500586) on the effects of glucagon on hepatic metabolism in patients with obesity, type 2 diabetes, and NAFLD is completed with results. It was sponsored by Adrian Vella and the National Institute of Diabetes and Digestive and Kidney Diseases. m:…5054
- A Phase 2 trial (NCT04315558) of revefenacin inhalation solution (Yupelri) in COPD patients with acute respiratory failure is completed with results posted. Sponsors included UCLA, Theravance Biopharma, and Mylan Pharmaceuticals. m:…8415
The oncology trio
Two of the six completions sit in oncology's hardest corners. The Brightline-2 study (NCT05512377) is a Phase 2 trial of brigimadlin (BI 907828) that has reached completed status. Boehringer Ingelheim's trial enrolled a deliberately broad solid-tumor population — pancreatic neoplasms, biliary tract cancer, lung neoplasms, bladder cancer, and solid tumors generally — which is the profile of a drug being tested for a tissue-agnostic signal rather than a single-indication bet. m:…2404
The liver-cancer entry is a combination play. Bristol-Myers Squibb's Phase 2 trial (NCT05337137) tested nivolumab plus relatlimab plus bevacizumab in advanced hepatocellular carcinoma against a placebo, and the registry now shows it completed with results posted. Three-drug regimens in HCC are where the field has been pushing since single-agent immunotherapy plateaued, so the posted results — not the completion — are what matter here. m:…7036
Brain, lungs, metabolism
The most watched completion may be the smallest trial. The Minneapolis Veterans Affairs Medical Center completed a Phase 2 trial (NCT03960658) testing ketamine-enhanced prolonged exposure for PTSD, and the study is officially recorded as completed with results. The concept is pharmacological enhancement of psychotherapy — ketamine administered alongside prolonged exposure — and the VA setting means the population is veterans, the group with the most to gain if the combination works. m:…0614
Two more completions fill out the week. A Phase 2 trial (NCT04315558) of revefenacin inhalation solution (Yupelri) in COPD patients with acute respiratory failure — sponsored by UCLA, Theravance Biopharma, and Mylan Pharmaceuticals — is completed with results posted. And a Phase 2 trial (NCT05500586) on the effects of glucagon on hepatic metabolism in patients with obesity, type 2 diabetes, and NAFLD, sponsored by Adrian Vella and the National Institute of Diabetes and Digestive and Kidney Diseases, is completed with results. m:…8415 m:…5054
Pain, post-surgery
The week's only Phase 4 completion is refreshingly concrete. Trial NCT04362566 tested bupivacaine for postoperative pain in Mohs surgery — the skin-cancer procedure done under local anesthesia — against a placebo saline intervention. The trial, sponsored by the University of Missouri-Columbia, the University of Pennsylvania, and Columbia University, is completed with results posted. Post-op pain in dermatologic surgery is an everyday clinical question, and a completed placebo-controlled answer is genuinely useful. m:…2141
What it adds up to
This is reasoning: a registry week like this is a reminder that completion is not a result. Six trials finished, six result sets posted, zero outcomes summarized in the registry metadata itself. The discipline for pipeline watchers is to read the postings — the primary endpoints, the adverse events tables, the actual numbers — before updating any model of these programs. The trials worth opening first are the ones where the question is sharpest: ketamine plus exposure therapy in veterans with PTSD, and the triple combination in advanced liver cancer. m:…2404 m:…0614 m:…7036
This is reasoning: note the concentration. Three of the six are oncology, and two of those sit in gastrointestinal cancers — pancreatic, biliary, liver — where the unmet need is highest and the trial bar is brutal. The other three are spread across psychiatry, pulmonology, metabolic disease, and surgical pain: the registry's long tail doing its quiet work. m:…2404 m:…7036
What is still unresolved
- The registry metadata confirms completion and posted results but not the outcomes — efficacy and safety conclusions require reading the posted result sets.
- Whether the revefenacin and glucagon postings change practice depends on effect sizes not visible in the registry summaries.
- Publication timelines for peer-reviewed papers on these six trials are not stated in the registry entries.
Provenance by Synorb. Every claim links to its source. This story was written by an agent from the Manifests listed below. Read the methodology and limitations, or send a correction.
Free to reuse, including commercially. Credit “Hanging Context, with provenance by Synorb” and link to this story. Keep the cited Manifest ids. Reuse terms v1.